Teleflex Incorporated

TFX▼

Teleflex Cuts 2026 Earnings Guidance After Weaker Second Quarter

Teleflex Incorporated reported second-quarter sales of US$570.33 million but lower net income of US$99.69 million year-on-year, and cut its 2026 GAAP EPS guidance to US$2.54 to US$2.84 while affirming revenue guidance of US$2.26 billion to US$2.28 billion. The company also completed a US$250 million repurchase of 1,900,000 shares and affirmed a quarterly US$0.34 dividend payable on September 30, 2026. The lowered earnings outlook and extended integration timelines for the Vascular Intervention acquisition are sharpening investor focus on how Teleflex converts its portfolio reshaping into sustainable profitability and cash returns.

TFX ▼

Simply Wall St·11dRead more ▾

TFX▼

Teleflex Cuts 2026 Revenue Growth Outlook as Vascular Intervention Integration Slows

Teleflex reduced its 2026 pro forma adjusted constant currency revenue growth guidance to 3.5%–4.5% from 4.5%–5.5%, citing a slower-than-expected integration of the vascular intervention business. The interventional segment saw revenue decline 1% in the second quarter, falling short of expectations due to ongoing order-to-cash transitions, distributor changes, and sales force realignment. Despite the headwinds, the company delivered better-than-expected revenue, adjusted margins, and adjusted EPS in Q2, with strength in vascular and surgical units. Teleflex also closed its OEM divestiture, generating approximately $1.5 billion in proceeds to fund debt reduction and share repurchases, including a $250 million buyback completed in the quarter and an additional $250 million accelerated share repurchase set to begin on August 7, 2026. The company raised its full-year adjusted EPS guidance to $6.90–$7.20, reflecting the benefit of share repurchases and lower net interest expense. New CEO Jason Weidman, who brings 20 years of interventional experience, expressed strong conviction in the long-term prospects of the interventional business and expects to provide more details on his strategic vision by the next earnings call.

TFX ▼

GuruFocus·20dRead more ▾

TFX▲

Teleflex secures FDA approval for freeze-dried plasma and completes $1.5 billion OEM sale

Teleflex has secured FDA approval for its EZPLAZ Freeze Dried Plasma and completed a $1.5 billion OEM divestiture, refocusing its portfolio. The stock has gained 13.71% over the past 90 days and delivered a 23.40% one-year total shareholder return. A widely followed analyst narrative estimates fair value at $148.55, slightly above the last close of $140.12, implying the stock is modestly undervalued. That narrative assumes annual revenue growth of 6.1% over the next three years and a profit margin recovery from 0.1% to 11.7%, though execution risks remain if UroLift weakness persists or Biotronik integration pressures margins.

TFX ▲

Simply Wall St·22dRead more ▾

Defense & Geopolitical Fragmentation▲

FDA Approves Teleflex's EZPLAZ, the First Licensed Freeze-Dried Plasma Product

Teleflex Incorporated announced that the U.S. FDA has approved its Biologics License Application for EZPLAZ Freeze Dried Plasma, making it the first FDA-licensed freeze-dried plasma product and Teleflex's first biologics license for a blood component. EZPLAZ is indicated for transfusion in adults with bleeding-related conditions requiring replacement of plasma coagulation factors, including uncontrolled hemorrhage, when plasma is needed and other plasma products are not available. Unlike current Emergency Use Authorization products packaged in glass bottles, EZPLAZ uses a patented flexible plastic bag technology designed for easier transport and storage in critical settings such as ambulances, hospitals, and battlefields. The Defense Health Agency partnered with Teleflex through its Warfighter Protection and Acute Care program to develop shelf-stable blood products for frontline medical teams. Teleflex shares closed Wednesday at $134.65, up 0.34%, and rose 1.75% in pre-market trading to $137.00.

TFX ▲

Defense & Geopolitical Fragmentation ▲

RTTNews·28dRead more ▾

TFX▲

BMO names Intuitive Surgical, Globus Medical, Teleflex as top MedTech picks

BMO Capital Markets has named Intuitive Surgical, Globus Medical, and Teleflex as its highest-conviction picks in the medical technology sector, initiating coverage with Outperform ratings and calling the beaten-down group a buying opportunity. Analyst Vik Chopra noted that MedTech stocks trade roughly 31% below their 10-year relative average, approaching the widest discount to the S&P 500 in a decade, while demand for hospital procedures remains strong. He attributed the weakness to fund flows and policy noise rather than fundamentals, describing the sector as under-owned and under-appreciated with the marginal buyer absent. Intuitive Surgical, his top pick, trades at about a 31% discount to its three-year historical multiple despite having the strongest fundamental profile among peers. Globus Medical was highlighted for sector-leading margin growth partly driven by its Nevro acquisition, and Teleflex was cited for a 2027 earnings inflection not yet reflected in consensus. Price targets were set at $518 for Intuitive Surgical, $94 for Globus Medical, and $159 for Teleflex.

GMED ▲ISRG ▲TFX ▲

Seeking Alpha·48dRead more ▾

TFX▼2

Surgical Equipment Stocks Post Strong Q1, Integra LifeSciences Shares Surge 64.9%

Surgical equipment and consumables specialty stocks reported a strong first quarter, with the four companies tracked by StockStory beating revenue consensus by 2.7% on average. Integra LifeSciences posted revenue of $391.9 million, up 2.4% year-on-year and 2.6% above estimates, while raising its full-year EPS guidance; its shares have surged 64.9% since the report. Intuitive Surgical delivered the biggest beat, with revenue of $2.77 billion exceeding expectations by 5.8%, though its stock fell 10.6%. Teleflex grew revenue 32.3% to $548.3 million but missed full-year EPS guidance, and LeMaitre Vascular reported $66.55 million in revenue, in line with estimates, while beating next-quarter EPS guidance.

IART ▲ISRG ▼TFX ▼LMAT

StockStory·64dRead more ▾

TFX▲

Teleflex Begins Enrollment in Global BIOMAG-III Pivotal Trial for Freesolve Resorbable Magnesium Scaffold

Teleflex has initiated enrollment in the BIOMAG-III Study, a landmark global pivotal trial evaluating its Freesolve Resorbable Magnesium Scaffold. The randomized controlled trial will enroll 1,859 patients at up to 120 sites worldwide, including up to 60 in the United States, and compare Freesolve RMS to Xience Drug-Eluting Stent on Target Lesion Failure at 12 months. The first U.S. patient was implanted by Dr. Itsik Ben-Dor at MedStar Health in Washington, D.C. Teleflex also announced that enrollment in the BIOMAG-II Study, a separate 1,861-patient randomized trial comparing Freesolve RMS to Xience DES across 20 countries in Europe and Asia Pacific, was completed ahead of schedule. Additionally, positive four-year data from the BIOMAG-I first-in-human study showed a 3.5% Target Lesion Failure rate with no new clinical events between two and four years.

TFX ▲

Business Wire·64dRead more ▾